[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @OzmosiHealth Ozmosi Ozmosi posts on X about more info, $pph, $xph, $ibb the most. They currently have XXXXX followers and XXX posts still getting attention that total XXXXX engagements in the last XX hours. ### Engagements: XXXXX [#](/creator/twitter::1055982930/interactions)  - X Week XXXXXX +105% - X Month XXXXXXX +32% - X Months XXXXXXX +12% - X Year XXXXXXXXX +87% ### Mentions: XX [#](/creator/twitter::1055982930/posts_active)  - X Week XXX -XX% - X Month XXX -XXXX% - X Months XXXXX +27% - X Year XXXXX +69% ### Followers: XXXXX [#](/creator/twitter::1055982930/followers)  - X Week XXXXX +8.90% - X Month XXXXX +11% - X Months XXXXX +24% - X Year XXXXX +42% ### CreatorRank: XXXXXXX [#](/creator/twitter::1055982930/influencer_rank)  ### Social Influence [#](/creator/twitter::1055982930/influence) --- **Social category influence** [stocks](/list/stocks) XXXX% [countries](/list/countries) XXXX% [finance](/list/finance) XXXX% [currencies](/list/currencies) XXXX% [cryptocurrencies](/list/cryptocurrencies) XXXX% [technology brands](/list/technology-brands) XXXX% **Social topic influence** [more info](/topic/more-info) #229, [$pph](/topic/$pph) #1, [$xph](/topic/$xph) #1, [$ibb](/topic/$ibb) #2, [$xbi](/topic/$xbi) #6, [$abvx](/topic/$abvx) 1.45%, [$krys](/topic/$krys) 0.33%, [approved](/topic/approved) 0.33%, [regulatory](/topic/regulatory) #85, [canada](/topic/canada) XXXX% **Top accounts mentioned or mentioned by** [@marketwirenews](/creator/undefined) [@towiu2](/creator/undefined) [@smantel](/creator/undefined) [@salmanfirat2](/creator/undefined) [@john06746191](/creator/undefined) [@stewdomer](/creator/undefined) [@dwill3000](/creator/undefined) [@chrismangum14](/creator/undefined) [@nicolem52807658](/creator/undefined) [@mitchellreed09](/creator/undefined) **Top assets mentioned** [Bitcoin Incognito (XBI)](/topic/$xbi) [Krystal Biotech, Inc. Common Stock (KRYS)](/topic/$krys) [Crinetics Pharmaceuticals, Inc. (CRNX)](/topic/$crnx) [Bristol-Myers Squibb Co (BMY)](/topic/$bmy) [Ionis Pharmaceuticals, Inc. Common Stock (IONS)](/topic/$ions) [IDEAYA Biosciences, Inc. Common Stock (IDYA)](/topic/$idya) [Revolution Medicines, Inc. Common Stock (RVMD)](/topic/$rvmd) [Gilead Sciences, Inc. (GILD)](/topic/$gild) [Agios Pharmaceuticals, Inc. (AGIO)](/topic/$agio) [SuperRare (RARE)](/topic/$rare) [Rhythm Pharmaceuticals, Inc. Common Stock (RYTM)](/topic/$rytm) [Axsome Therapeutics, Inc (AXSM)](/topic/$axsm) [Neurocrine Biosciences, Inc. (NBIX)](/topic/$nbix) [Vir Biotechnology, Inc. Common Stock (VIR)](/topic/$vir) [Arvinas, Inc (ARVN)](/topic/$arvn) [Halozyme Therapeutics, Inc. (HALO)](/topic/$halo) [Alnylam Pharmaceuticals, Inc. (ALNY)](/topic/$alny) [Corcept Therapeutics Inc. (CORT)](/topic/$cort) [BioMarin Pharmaceutical, Inc. (BMRN)](/topic/$bmrn) [Biogen Inc (BIIB)](/topic/$biib) [Eli Lilly and Company (LLY)](/topic/$lly) [Dyne Therapeutics, Inc. Common Stock (DYN)](/topic/$dyn) [Oruka Therapeutics, Inc. Common Stock (ORKA)](/topic/$orka) [Johnson & Johnson (JNJ)](/topic/$jnj) ### Top Social Posts [#](/creator/twitter::1055982930/posts) --- Top posts by engagements in the last XX hours "$CRDL TSX:CRDL Cardiol Therapeutics locks database for Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947620686476021854) 2025-07-22 11:32:11 UTC 2626 followers, XXX engagements "$NRSN Join Aaron Lazar and NeuroSense CEO Alon Ben-Noon in a live podcast discussing ALS science PrimeC's strategies and community impact. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947643337483112663) 2025-07-22 13:02:11 UTC 2628 followers, XXX engagements "$EVAX Evaxion to share two-year clinical efficacy results from phase X trial of AI-created personalized cancer vaccine EVX-01 at ESMO Congress 2025. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948738137603420212) 2025-07-25 13:32:32 UTC 2633 followers, XXX engagements "$CRNX Crinetics will present new long-term data showing lasting control of oral PALSONIFY in Acromegaly at ENDO 2025. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1944517755635630449) 2025-07-13 22:02:14 UTC 2633 followers, XXX engagements "🚀🚨 BIOPHARM CATALYST ALERT 📆 $AGIO Agios will present Phase X Anemia Sickle Cell Data for Mitapivat (PKR Activator - Small Molecule) tomorrow 👀"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1932757800327000094) 2025-06-11 11:12:23 UTC 2633 followers, XXX engagements "Sobi announces FDA approval of Doptelet for treating thrombocytopenia in children aged 1+ with persistent or chronic ITP. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948700335159345531) 2025-07-25 11:02:19 UTC 2633 followers, XXX engagements "$WALD Waldencast buys Novaestiq Corp. and U.S. rights for Saypha injectable hyaluronic acid gel line under Obagi Medical brand. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947975586250662391) 2025-07-23 11:02:26 UTC 2633 followers, XXX engagements "$BMY Bristol Myers Squibb's sNDA for Sotyktu (deucravacitinib) in treating active Psoriatic Arthritis accepted for review in four regions worldwide. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947250723793866964) 2025-07-21 11:02:05 UTC 2628 followers, XXX engagements "$ATRA Atara Biotherapeutics reports FDA acceptance and priority review of Biologics License Application for Tab-cel to treat EBV+ post-transplant lymphoproliferative disease. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948360684540219405) 2025-07-24 12:32:40 UTC 2633 followers, XXX engagements "Pharma/Biotech Highlights: $MRNS: Marinus Pharma reports Q4 2023 earnings. $RYTM: Rhythm Pharma screens for obesity treatment. $NWPHF: Evenamide shows promise in treating TRS. $RARE: Ultragenyx's Evkeeza recommended in UK"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1743020790495289398) 2024-01-04 21:25:14 UTC 2627 followers, XXX engagements "🚀🚨 BIOPHARM CATALYST ALERT 📆 $CRNX Crinetics will present Phase X Adrenal Hyperplasia Congenital Data for Atumelnant (MCR Antagonist - Small Molecule) tomorrow 👀"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1943629425394045011) 2025-07-11 11:12:20 UTC 2633 followers, XXX engagements "Fast-track designation granted by FDA for DualityBio's Next-Generation HER3 ADC DB-1310. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947484861507506475) 2025-07-22 02:32:28 UTC 2632 followers, XXX engagements "$APTOF TSX:APS Aptose gets second advance from Hanmi Pharmaceutical for Tuspetinib development in AML triplet therapy. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945235025827651995) 2025-07-15 21:32:25 UTC 2630 followers, XXX engagements "$ALDX Aldeyra Therapeutics' NDA for Reproxalap in treating Dry Eye Disease accepted by FDA for review. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945808936600514875) 2025-07-17 11:32:56 UTC 2633 followers, XXX engagements "$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X trials of Obefazimod in treating moderate-severe ulcerative colitis. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947832210083746182) 2025-07-23 01:32:42 UTC 2630 followers, XXX engagements "$BIVI BioVie showcased data at the 2nd World Conference on Aging highlighting potential age deceleration with Bezisterim treatment compared to placebo on XX different biological clocks. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948360676050931980) 2025-07-24 12:32:38 UTC 2632 followers, XXX engagements "$KRYS First patient dosed in Phase 1/2 trial of KB801 for Neurotrophic Keratitis treatment announces Krystal Biotech. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1942909752713134281) 2025-07-09 11:32:37 UTC 2633 followers, XXX engagements "Aicuris completed enrollment for pivotal trial of Pritelivir for refractory herpes simplex in immunocompromised patients. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948308001208852954) 2025-07-24 09:03:19 UTC 2632 followers, XXX engagements "CHMP recommends VORANIGO (vorasidenib) for Grade X IDH-mutant Diffuse Glioma in adults and adolescents. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948723006479761764) 2025-07-25 12:32:24 UTC 2633 followers, XXX engagements "FDA fast tracks Addyi for postmenopausal women with low sexual desire enabling quicker access to treatment. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948360664092922144) 2025-07-24 12:32:35 UTC 2632 followers, XXX engagements "$KRYS Jeune reports successful Phase X results for KB304 in treating moderate to severe dcollet wrinkles with noticeable aesthetic improvements. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948360697089556878) 2025-07-24 12:32:43 UTC 2633 followers, XXX engagements "$ARGX argenx progresses clinical development of ARGX-119 for Congenital Myasthenic Syndromes. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1939557671314817282) 2025-06-30 05:32:38 UTC 2626 followers, XXX engagements "$PARIS:AB AB Science has been approved by multiple European countries to begin phase X study on masitinib for ALS. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948262436987187596) 2025-07-24 06:02:16 UTC 2633 followers, XXX engagements "$AXDX Accelerate Diagnostics announces financial results for Q4 and full-year 2024. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1903266035685593583) 2025-03-22 02:02:38 UTC 2633 followers, XXX engagements "Akeso starts Phase III trial of Ivonescimab for Pancreatic Cancer with first patient enrollment announced. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948194557948227758) 2025-07-24 01:32:32 UTC 2634 followers, XXX engagements "$IVBIY Phase X results of Innovent Biologics' IBI343 for advanced gastric/esophageal adenocarcinoma published in Nature Medicine. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945642697097908598) 2025-07-17 00:32:21 UTC 2633 followers, XXX engagements "$AXSM Axsome Therapeutics resolves patent dispute over SUNOSI (solriamfetol) with Hetero Labs Ltd. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1927357641740751201) 2025-05-27 13:34:05 UTC 2633 followers, XXX engagements "AGT announces promising results from AGT103-T HIV Functional Cure Program presented as late-breaker at International AIDS Society 2025. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947681148131586117) 2025-07-22 15:32:26 UTC 2628 followers, XXX engagements "$ATRA Pierre Fabre Pharmaceuticals Inc. reveals FDA acceptance and priority review of Biologics License Application for Tabelecleucel for EBV+ PTLD treatment. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948368151680614402) 2025-07-24 13:02:20 UTC 2633 followers, XXX engagements "$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X outcomes for ABTECT trials on Obefazimod an oral miR-124 enhancer for moderate to severe ulcerative colitis. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947839761181512142) 2025-07-23 02:02:42 UTC 2628 followers, XXX engagements "$NBIX Neurocrine Biosciences reveals 1-year data demonstrating sustained effectiveness of CRENESSITY (crinecerfont) in adult patients at ENDO 2025. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1944744285708206082) 2025-07-14 13:02:23 UTC 2633 followers, XXX engagements "Nxera Pharma to get $15M from Neurocrine Biosciences after dosing first patient in Phase X trial for NBI-1117568. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1929682542350975244) 2025-06-02 23:32:24 UTC 2633 followers, XXX engagements "$ABVX PARIS:ABVX PARIS:FR Abivax reports encouraging Phase X results from ABTECT trials on Obefazimod for moderate to severe ulcerative colitis. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947764286136455425) 2025-07-22 21:02:48 UTC 2632 followers, 1498 engagements "Novo Nordisk's Alhemo (concizumab) may be approved to treat haemophilia A and B without inhibitors following positive opinion from European regulatory authority. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948700341593407540) 2025-07-25 11:02:21 UTC 2633 followers, XXX engagements "Windward Bio begins global Phase X asthma trial for WIN378 an anti-TSLP monoclonal antibody with potential as long-acting and best-in-disease treatment. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948005787365986705) 2025-07-23 13:02:26 UTC 2633 followers, XXX engagements "Inotrem introduces revolutionary precision medicine approach for Nangibotide trials in septic shock treatment. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948013356524445710) 2025-07-23 13:32:31 UTC 2633 followers, XXX engagements "$IONS CHMP suggests approving TRYNGOLZA (olezarsen) in the EU for familial chylomicronemia syndrome (FCS). More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948707876895367500) 2025-07-25 11:32:17 UTC 2633 followers, XXX engagements "The Phase II trial of KX-826 Tincture XXX% for male adult AGA in China met its primary endpoint. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948734629294604815) 2025-07-25 13:18:36 UTC 2633 followers, XXX engagements "$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X results in ABTECT trials for Obefazimod in moderate to severe ulcerative colitis. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947809437676408951) 2025-07-23 00:02:13 UTC 2629 followers, XXX engagements "$VSTM Fast track designation granted to Verastem Oncology for VS-7375 in treating KRAS G12D-mutated Pancreatic Cancer. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948345506125750460) 2025-07-24 11:32:21 UTC 2632 followers, XXX engagements "$PARIS:AB AB Science has received approval from several European countries to begin the confirmatory phase X study with masitinib in ALS. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948285139425054772) 2025-07-24 07:32:29 UTC 2631 followers, XXX engagements "$VIR First patient dosed in Phase X trial of EGFR-targeting VIR-5525 for solid tumors by Vir Biotechnology. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948360703917875604) 2025-07-24 12:32:45 UTC 2633 followers, XXX engagements "$IDYA IDEAYA Biosciences to present Phase X Clinical Trial of Neoadjuvant Darovasertib at ESMO 2025 for Primary Uveal Melanoma. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948375737167409474) 2025-07-24 13:32:29 UTC 2633 followers, XXX engagements "First patient dosed in Phase 1b/2a trial of Procizumab a monoclonal antibody targeting shock's biological driver. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947960470293684531) 2025-07-23 10:02:22 UTC 2626 followers, XXX engagements "$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X outcomes in ABTECT trials using Obefazimod for ulcerative colitis. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947794374701793596) 2025-07-22 23:02:21 UTC 2633 followers, XXX engagements "$ARVN Arvinas reveals preclinical data for ARV-393 a PROTAC BCL6 Degrader at the 2025 EHA Congress. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1933487579435053441) 2025-06-13 11:32:16 UTC 2633 followers, XXX engagements "$HALO DARZALEX Faspro approved by EU Commission for adult patients with Smouldering Multiple Myeloma. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948051067931177115) 2025-07-23 16:02:22 UTC 2632 followers, XXX engagements "$HOTH Hoth Therapeutics partners with VA for GDNF research targeting obesity and fatty liver. Study underway comparing GDNF to Semaglutide. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947635807444959541) 2025-07-22 12:32:16 UTC 2629 followers, XXX engagements "$ONCY TSX:ONC Key Opinion Leader Event sheds light on Pelareorep's promising data in pancreatic and gastrointestinal fields highlighting its future potential. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948020937611464916) 2025-07-23 14:02:38 UTC 2633 followers, XXX engagements "$PMN U.S. FDA grants ProMIS Neurosciences Fast Track Designation for PMN310 in Alzheimer's Disease treatment. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947273427477549322) 2025-07-21 12:32:18 UTC 2632 followers, XXX engagements "$CADL Candel Therapeutics obtains EMA Orphan Designation for CAN-2409 for Pancreatic Cancer treatment. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948360670141141441) 2025-07-24 12:32:37 UTC 2632 followers, XXX engagements "Reunion Neuroscience reports publication of RE104 Phase X Data in The Journal of Clinical Psychopharmacology. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947620693241434545) 2025-07-22 11:32:12 UTC 2626 followers, XXX engagements "$BCDA BioCardia wants to meet with Japan PMDA to talk about getting approval for CardiAMP Cell Therapy in Ischemic Heart Failure. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948375730641043774) 2025-07-24 13:32:27 UTC 2633 followers, XXX engagements "$RVMD Revolution Medicines announces publication in Science on Zoldonrasib a selective inhibitor for RAS(ON) G12D. Discovery and development detailed in peer-reviewed paper. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948473855816659447) 2025-07-24 20:02:22 UTC 2633 followers, XXX engagements "$ALNY OXLUMO (lumasiran injection) is now reimbursed in Canada for treating Primary Hyperoxaluria Type X (PH1) in pediatric and adult patients. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1940456256696996052) 2025-07-02 17:03:18 UTC 2627 followers, XXX engagements "$PHGE BiomX starts Phase 2b trial for BX004 in Cystic Fibrosis patients first patient dosed successfully. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1944744294470078780) 2025-07-14 13:02:26 UTC 2633 followers, XXX engagements "$ZVRA MIPLYFFA (arimoclomol) by Zevra Therapeutics will be highlighted in presentations at the National Niemann Pick Disease Foundation Conference. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1943634424681431183) 2025-07-11 11:32:12 UTC 2627 followers, XXX engagements "$GILD European Medicines Agency grants Gilead positive CHMP opinions for twice-yearly Lenacapavir for HIV prevention under accelerated review. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948647479479845145) 2025-07-25 07:32:17 UTC 2632 followers, XXX engagements "$RVMD FDA grants Breakthrough Therapy Designation to Revolution Medicines' Elironrasib. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947998237060964513) 2025-07-23 12:32:26 UTC 2633 followers, XXX engagements "Diakonos Oncology reports first patient dosed in Phase X trial of DOC1021 for Glioblastoma. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947635820032032822) 2025-07-22 12:32:19 UTC 2627 followers, XXX engagements "ReAlta Life Sciences releases data showing RLS-0071 decreases brain inflammation in preclinical hypoxic ischemic encephalopathy model. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947635814181310641) 2025-07-22 12:32:18 UTC 2626 followers, XXX engagements "$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X outcomes for ABTECT trials on Obefazimod in treating Ulcerative Colitis. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947786816930910555) 2025-07-22 22:32:19 UTC 2630 followers, XXX engagements "Canada approves Blenrep combos for relapsed/refractory multiple myeloma treatment. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947983118478278810) 2025-07-23 11:32:21 UTC 2632 followers, XXX engagements "Bayer shares regulatory update on Elinzanetant for treating moderate to severe menopause-induced hot flashes. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948790970214219824) 2025-07-25 17:02:28 UTC 2633 followers, XXX engagements "First patient dosed by OncoC4 with potential best-in-class PD-1/VEGF bispecific antibody AI-081 in Phase X of BIPAVE-001 trial for solid tumors in US. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947620709531889789) 2025-07-22 11:32:16 UTC 2626 followers, XXX engagements "$CORT New Drug Application submitted by Corcept for Relacorilant intended for patients with Platinum-Resistant Ovarian Cancer. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1944736748279627979) 2025-07-14 12:32:26 UTC 2633 followers, XXX engagements "Apnimed announces positive results from Phase X trial of AD109 showing potential as first oral pill for obstructive sleep apnea. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947968042648154326) 2025-07-23 10:32:27 UTC 2632 followers, XXX engagements "$ZVRA Zevra Therapeutics to present MIPLYFFA and OLPRUVA at SERGG Annual Meeting. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1946178701269611001) 2025-07-18 12:02:15 UTC 2626 followers, XXX engagements "Ammonium Chloride Market projected to reach $XXXX billion by 2034. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948043747507544398) 2025-07-23 15:33:16 UTC 2632 followers, XXX engagements "$BMRN BioMarin shares five-year Phase X data confirming effectiveness and safety of ROCTAVIAN at International Society on Thrombosis and Haemostasis 2025 Congress. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1937504076075532326) 2025-06-24 13:32:23 UTC 2633 followers, XXX engagements "$SLDB FDA grants Fast Track Designation to Solid Biosciences for SGT-501 a first-of-its-kind gene therapy for CPVT. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947998243591500270) 2025-07-23 12:32:27 UTC 2632 followers, XXX engagements "$IDYA IDEAYA and Hengrui reveal IDE849 for IASLC 2025. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947711300655845785) 2025-07-22 17:32:15 UTC 2630 followers, XXX engagements "$CELC First patient in Phase X VIKTORIA-2 trial of Gedatolisib for HR+/HER2Advanced Breast Cancer dosed by Celcuity as first-line treatment. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948481423783936447) 2025-07-24 20:32:27 UTC 2633 followers, XXX engagements "$KALV KalVista Pharmaceuticals gets favorable CHMP view for Sebetralstat for the management of Hereditary Angioedema Attacks. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948723012272095368) 2025-07-25 12:32:26 UTC 2633 followers, XXX engagements "Polivy (polatuzumab vedotin) by Roche Canada is now publicly reimbursed in Quebec for first-line treatment of large B-cell lymphoma in adults. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947650899213750497) 2025-07-22 13:32:14 UTC 2627 followers, XXX engagements "$ACET Adicet Bio dosed the first Systemic Sclerosis patient in Phase X trial of ADI-001 for Autoimmune Diseases. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948338030974226558) 2025-07-24 11:02:39 UTC 2633 followers, XXX engagements "ANZUPGO Cream is the first FDA-approved treatment for moderate-to-severe Chronic Hand Eczema in adults. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948126569308000548) 2025-07-23 21:02:23 UTC 2633 followers, XXX engagements "$REPL FDA issues Complete Response Letter to Replimune for RP1 Biologics License Application for Advanced Melanoma treatment. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947620700803792908) 2025-07-22 11:32:14 UTC 2626 followers, 1181 engagements "$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X results for ABTECT 8-week induction trials of Obefazimod in treating moderate to severe ulcerative colitis. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947816984931868798) 2025-07-23 00:32:12 UTC 2629 followers, XXX engagements "$ANNX Enrollment in pivotal Phase X ARCHER II trial of Vonaprument (formerly ANX007) for Dry AMD with Geographic Atrophy completed by Annexon. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948338024838013218) 2025-07-24 11:02:38 UTC 2633 followers, XXX engagements "$IONS New study in JACI In Practice shows how donidalorsen benefits HAE patients who switched from other treatments in Phase X OASISplus data. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947258350670127142) 2025-07-21 11:32:23 UTC 2633 followers, XXX engagements "$TNXP Tonix Pharmaceuticals will present new data on Mpox and smallpox vaccine TNX-801 at Vaccine Congress 2025. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1943272668029219032) 2025-07-10 11:34:42 UTC 2633 followers, 3297 engagements "$PRAX Praxis Precision Medicines granted FDA Breakthrough Therapy Designation for Relutrigine to treat seizures related to SCN2A and SCN8A Developmental and Epileptic Encephalopathies. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945823930666934771) 2025-07-17 12:32:31 UTC 2632 followers, XXX engagements "$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X trials for ABTECT 8-week induction using Obefazimod for moderate to severe ulcerative colitis a first-of-its-kind oral miR-124 enhancer. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947771757282398451) 2025-07-22 21:32:29 UTC 2629 followers, XXX engagements "$CGTX Cognition Therapeutics releases study examining how Zervimesine shields neurons and synapses in Alzheimer's disease. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947265857270534315) 2025-07-21 12:02:13 UTC 2630 followers, XXX engagements "$IVBIY Innovent initiates Phase X trial for IBI354 a new HER2 ADC in platinum-resistant ovarian cancer. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1903968121867890788) 2025-03-24 00:32:28 UTC 2627 followers, XXX engagements "$BIIB SAGE CHMP gives positive opinion for ZURZUVAE in treating postpartum depression in women. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948707870725603800) 2025-07-25 11:32:16 UTC 2633 followers, XXX engagements "$IRON Disc Medicine confirms plan to submit NDA for Bitopertin in EPP in October 2025 after positive pre-NDA meeting announcement. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947273409840488919) 2025-07-21 12:32:14 UTC 2633 followers, XXX engagements "$IMAB I-Mab releases Givastomig Monotherapy Data in Clinical Cancer Research. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1939784175571345836) 2025-06-30 20:32:41 UTC 2628 followers, XXX engagements "$PARIS:SAN Sanofi's Sarclisa granted EU approval for treating eligible newly diagnosed multiple myeloma. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948610358434025668) 2025-07-25 05:04:47 UTC 2633 followers, XXX engagements "$ATYR aTyr Pharma reports completion of Phase X EFZO-FIT study of Efzofitimod in patients with pulmonary sarcoidosis. Last patient visit announced. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947628237364072806) 2025-07-22 12:02:11 UTC 2630 followers, XXX engagements "Eisai to share four-year efficacy and safety results for continuous treatment with lecanemab at Alzheimer's Association International Conference 2025. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947447166949331097) 2025-07-22 00:02:41 UTC 2632 followers, XXX engagements "Prilenia and Ferrer give news on European process for Pridopidine in Huntington's Disease regulatory approval. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948738125125353707) 2025-07-25 13:32:29 UTC 2633 followers, XXX engagements "$BMY Bristol Myers Squibb reports Phase X INDEPENDENCE Trial topline findings for Reblozyl in adults with Myelofibrosis-Associated Anemia. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1946163606707667256) 2025-07-18 11:02:16 UTC 2633 followers, XXX engagements "$GILD Gilead shares new research on lenacapavir's effectiveness for HIV prevention at IAS 2025. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1944759376243544306) 2025-07-14 14:02:21 UTC 2631 followers, XXX engagements "$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X outcomes for ABTECT 8-Week trial on Obefazimod for Ulcerative Colitis. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947779263241101458) 2025-07-22 22:02:19 UTC 2629 followers, XXX engagements "Eisai will share four-year efficacy and safety data on continuous treatment with Lecanemab at the Alzheimer's Association International Conference 2025. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947567825000009931) 2025-07-22 08:02:08 UTC 2633 followers, XXX engagements "$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X trial results for ABTECT 8-week induction studies on Obefazimod a unique oral miR-124 enhancer for ulcerative colitis. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947847592425230474) 2025-07-23 02:33:49 UTC 2633 followers, XXX engagements "Long-acting fully human anti-TSLP antibody HBM9378/WIN378 enters global Phase X POLARIS trial for asthma treatment. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948020944741818570) 2025-07-23 14:02:40 UTC 2633 followers, XXX engagements "$ADAG Adagene provides regulatory update on clinical plan for Muzastotug in microsatellite stable colorectal cancer after successful FDA meeting. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945076458277495035) 2025-07-15 11:02:20 UTC 2631 followers, XXX engagements "$UNCY Unicycive Therapeutics releases Oxylanthanum Carbonate trial results in Clinical Journal of the American Society of Nephrology. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948360691016241171) 2025-07-24 12:32:42 UTC 2633 followers, XXX engagements "$ALMS Alumis finishes enrolling patients in global LUMUS Phase 2b trial of ESK-001 an advanced oral TYK2 inhibitor for treating Systemic Lupus Erythematosus. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948345499792322822) 2025-07-24 11:32:20 UTC 2633 followers, XXX engagements "$ZVRA Zevra Therapeutics reveals data from open label extension proving MIPLYFFA's long-term effectiveness in treating NPC published in Journal of Molecular Genetics and Metabolism. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945453971688288631) 2025-07-16 12:02:26 UTC 2627 followers, XXX engagements "$LTRN Lantern Pharma announces full response in highly treated lymphoma patient with LP-284 in Phase X trial. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947990646461231375) 2025-07-23 12:02:16 UTC 2633 followers, XXX engagements "$LLY CHMP has given a positive opinion on Donanemab for use in early symptomatic Alzheimer's disease. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948692964756303932) 2025-07-25 10:33:02 UTC 2633 followers, XXX engagements "$ABVX PARIS:ABVX PARIS:FR Abivax reports promising Phase X findings on ABTECT 8-Week Induction Trials for Obefazimod an oral miR-124 enhancer for ulcerative colitis. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947757076627001502) 2025-07-22 20:34:09 UTC 2633 followers, 1011 engagements "$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X results for ABTECT 8-Week Induction Trials of Obefazimod in patients with moderate to severe ulcerative colitis. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947801890529677601) 2025-07-22 23:32:13 UTC 2630 followers, XXX engagements "$ENVB Enveric Biosciences gets second U.S. patent allowance for non-hallucinogenic mescaline derivatives in EVM401 Series. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947998249929072722) 2025-07-23 12:32:29 UTC 2633 followers, XXX engagements "$KRYS Japan's Ministry of Health Labour and Welfare approves Krystal Biotech's VYJUVEK for treating Dystrophic Epidermolysis Bullosa. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948738131379060971) 2025-07-25 13:32:30 UTC 2633 followers, XXX engagements "$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X outcomes in ABTECT 8-Week trials for Obefazimod a novel miR-124 enhancer for treatment of Ulcerative Colitis. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947824536189342085) 2025-07-23 01:02:12 UTC 2630 followers, XXX engagements "$ENVB Enveric Biosciences' top drug candidate EB-003 shows promise in preclinical PTSD model with positive effects. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1945114198767514092) 2025-07-15 13:32:18 UTC 2633 followers, 2776 engagements "$RCKT FDA Clinical Hold on RP-A501 Trial causes Rocket Pharmaceuticals (RCKT) stock to plummet and leads to Class Action lawsuit by Hagens Berman. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948149744532144136) 2025-07-23 22:34:28 UTC 2633 followers, XXX engagements "Kelun-Biotech's partner Windward Bio starts global Phase X trial for SKB378/WIN378 in asthma. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948013362295763063) 2025-07-23 13:32:32 UTC 2634 followers, XXX engagements "$DYN Dyne Therapeutics receives FDA Breakthrough Therapy Designation for DYNE-101 in DM1 plans for accelerated approval discussed in Type C Meeting. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1934929648636580017) 2025-06-17 11:02:32 UTC 2632 followers, XXX engagements "$ORKA Oruka Therapeutics gets IND clearance for EVERLAST-A Phase 2a trial of ORKA-001 in Psoriasis. Phase X data to be detailed at EADV in September. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947258375143817664) 2025-07-21 11:32:29 UTC 2632 followers, XXX engagements "Alkeus Pharmaceuticals to present Gildeuretinol data at ASRS 43rd Annual Meeting on July 29-August X. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947998230656303521) 2025-07-23 12:32:24 UTC 2633 followers, XXX engagements "$JNJ Johnson & Johnson aims for US FDA approval of icotrokinra to change treatment for adults and teens with plaque psoriasis. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1947280960367804609) 2025-07-21 13:02:14 UTC 2632 followers, XXX engagements "Hillhurst Biopharmaceuticals administers first dose in Phase 2a trial for HBI-002 a new treatment for Sickle Cell Disease. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948111515078504861) 2025-07-23 20:02:34 UTC 2633 followers, XXX engagements "$CMND CSE:CMND Clearmind Medicine finishes starting trial at top Israeli site for Phase I/IIa trial of CMND-100 for Alcohol Use Disorder. More Info: $XBI $IBB $XPH $PPH"  [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1948005780361495026) 2025-07-23 13:02:24 UTC 2633 followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@OzmosiHealth Ozmosi
Ozmosi posts on X about more info, $pph, $xph, $ibb the most. They currently have XXXXX followers and XXX posts still getting attention that total XXXXX engagements in the last XX hours.
Engagements: XXXXX #
- X Week XXXXXX +105%
- X Month XXXXXXX +32%
- X Months XXXXXXX +12%
- X Year XXXXXXXXX +87%
Mentions: XX #
- X Week XXX -XX%
- X Month XXX -XXXX%
- X Months XXXXX +27%
- X Year XXXXX +69%
Followers: XXXXX #
- X Week XXXXX +8.90%
- X Month XXXXX +11%
- X Months XXXXX +24%
- X Year XXXXX +42%
CreatorRank: XXXXXXX #
Social Influence #
Social category influence stocks XXXX% countries XXXX% finance XXXX% currencies XXXX% cryptocurrencies XXXX% technology brands XXXX%
Social topic influence more info #229, $pph #1, $xph #1, $ibb #2, $xbi #6, $abvx 1.45%, $krys 0.33%, approved 0.33%, regulatory #85, canada XXXX%
Top accounts mentioned or mentioned by @marketwirenews @towiu2 @smantel @salmanfirat2 @john06746191 @stewdomer @dwill3000 @chrismangum14 @nicolem52807658 @mitchellreed09
Top assets mentioned Bitcoin Incognito (XBI) Krystal Biotech, Inc. Common Stock (KRYS) Crinetics Pharmaceuticals, Inc. (CRNX) Bristol-Myers Squibb Co (BMY) Ionis Pharmaceuticals, Inc. Common Stock (IONS) IDEAYA Biosciences, Inc. Common Stock (IDYA) Revolution Medicines, Inc. Common Stock (RVMD) Gilead Sciences, Inc. (GILD) Agios Pharmaceuticals, Inc. (AGIO) SuperRare (RARE) Rhythm Pharmaceuticals, Inc. Common Stock (RYTM) Axsome Therapeutics, Inc (AXSM) Neurocrine Biosciences, Inc. (NBIX) Vir Biotechnology, Inc. Common Stock (VIR) Arvinas, Inc (ARVN) Halozyme Therapeutics, Inc. (HALO) Alnylam Pharmaceuticals, Inc. (ALNY) Corcept Therapeutics Inc. (CORT) BioMarin Pharmaceutical, Inc. (BMRN) Biogen Inc (BIIB) Eli Lilly and Company (LLY) Dyne Therapeutics, Inc. Common Stock (DYN) Oruka Therapeutics, Inc. Common Stock (ORKA) Johnson & Johnson (JNJ)
Top Social Posts #
Top posts by engagements in the last XX hours
"$CRDL TSX:CRDL Cardiol Therapeutics locks database for Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis. More Info: $XBI $IBB $XPH $PPH"
@OzmosiHealth on X 2025-07-22 11:32:11 UTC 2626 followers, XXX engagements
"$NRSN Join Aaron Lazar and NeuroSense CEO Alon Ben-Noon in a live podcast discussing ALS science PrimeC's strategies and community impact. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 13:02:11 UTC 2628 followers, XXX engagements
"$EVAX Evaxion to share two-year clinical efficacy results from phase X trial of AI-created personalized cancer vaccine EVX-01 at ESMO Congress 2025. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-25 13:32:32 UTC 2633 followers, XXX engagements
"$CRNX Crinetics will present new long-term data showing lasting control of oral PALSONIFY in Acromegaly at ENDO 2025. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-13 22:02:14 UTC 2633 followers, XXX engagements
"🚀🚨 BIOPHARM CATALYST ALERT 📆 $AGIO Agios will present Phase X Anemia Sickle Cell Data for Mitapivat (PKR Activator - Small Molecule) tomorrow 👀" @OzmosiHealth on X 2025-06-11 11:12:23 UTC 2633 followers, XXX engagements
"Sobi announces FDA approval of Doptelet for treating thrombocytopenia in children aged 1+ with persistent or chronic ITP. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-25 11:02:19 UTC 2633 followers, XXX engagements
"$WALD Waldencast buys Novaestiq Corp. and U.S. rights for Saypha injectable hyaluronic acid gel line under Obagi Medical brand. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 11:02:26 UTC 2633 followers, XXX engagements
"$BMY Bristol Myers Squibb's sNDA for Sotyktu (deucravacitinib) in treating active Psoriatic Arthritis accepted for review in four regions worldwide. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 11:02:05 UTC 2628 followers, XXX engagements
"$ATRA Atara Biotherapeutics reports FDA acceptance and priority review of Biologics License Application for Tab-cel to treat EBV+ post-transplant lymphoproliferative disease. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-24 12:32:40 UTC 2633 followers, XXX engagements
"Pharma/Biotech Highlights: $MRNS: Marinus Pharma reports Q4 2023 earnings. $RYTM: Rhythm Pharma screens for obesity treatment. $NWPHF: Evenamide shows promise in treating TRS. $RARE: Ultragenyx's Evkeeza recommended in UK" @OzmosiHealth on X 2024-01-04 21:25:14 UTC 2627 followers, XXX engagements
"🚀🚨 BIOPHARM CATALYST ALERT 📆 $CRNX Crinetics will present Phase X Adrenal Hyperplasia Congenital Data for Atumelnant (MCR Antagonist - Small Molecule) tomorrow 👀" @OzmosiHealth on X 2025-07-11 11:12:20 UTC 2633 followers, XXX engagements
"Fast-track designation granted by FDA for DualityBio's Next-Generation HER3 ADC DB-1310. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 02:32:28 UTC 2632 followers, XXX engagements
"$APTOF TSX:APS Aptose gets second advance from Hanmi Pharmaceutical for Tuspetinib development in AML triplet therapy. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-15 21:32:25 UTC 2630 followers, XXX engagements
"$ALDX Aldeyra Therapeutics' NDA for Reproxalap in treating Dry Eye Disease accepted by FDA for review. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-17 11:32:56 UTC 2633 followers, XXX engagements
"$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X trials of Obefazimod in treating moderate-severe ulcerative colitis. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 01:32:42 UTC 2630 followers, XXX engagements
"$BIVI BioVie showcased data at the 2nd World Conference on Aging highlighting potential age deceleration with Bezisterim treatment compared to placebo on XX different biological clocks. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-24 12:32:38 UTC 2632 followers, XXX engagements
"$KRYS First patient dosed in Phase 1/2 trial of KB801 for Neurotrophic Keratitis treatment announces Krystal Biotech. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-09 11:32:37 UTC 2633 followers, XXX engagements
"Aicuris completed enrollment for pivotal trial of Pritelivir for refractory herpes simplex in immunocompromised patients. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-24 09:03:19 UTC 2632 followers, XXX engagements
"CHMP recommends VORANIGO (vorasidenib) for Grade X IDH-mutant Diffuse Glioma in adults and adolescents. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-25 12:32:24 UTC 2633 followers, XXX engagements
"FDA fast tracks Addyi for postmenopausal women with low sexual desire enabling quicker access to treatment. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-24 12:32:35 UTC 2632 followers, XXX engagements
"$KRYS Jeune reports successful Phase X results for KB304 in treating moderate to severe dcollet wrinkles with noticeable aesthetic improvements. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-24 12:32:43 UTC 2633 followers, XXX engagements
"$ARGX argenx progresses clinical development of ARGX-119 for Congenital Myasthenic Syndromes. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-06-30 05:32:38 UTC 2626 followers, XXX engagements
"$PARIS:AB AB Science has been approved by multiple European countries to begin phase X study on masitinib for ALS. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-24 06:02:16 UTC 2633 followers, XXX engagements
"$AXDX Accelerate Diagnostics announces financial results for Q4 and full-year 2024. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-03-22 02:02:38 UTC 2633 followers, XXX engagements
"Akeso starts Phase III trial of Ivonescimab for Pancreatic Cancer with first patient enrollment announced. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-24 01:32:32 UTC 2634 followers, XXX engagements
"$IVBIY Phase X results of Innovent Biologics' IBI343 for advanced gastric/esophageal adenocarcinoma published in Nature Medicine. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-17 00:32:21 UTC 2633 followers, XXX engagements
"$AXSM Axsome Therapeutics resolves patent dispute over SUNOSI (solriamfetol) with Hetero Labs Ltd. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-05-27 13:34:05 UTC 2633 followers, XXX engagements
"AGT announces promising results from AGT103-T HIV Functional Cure Program presented as late-breaker at International AIDS Society 2025. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 15:32:26 UTC 2628 followers, XXX engagements
"$ATRA Pierre Fabre Pharmaceuticals Inc. reveals FDA acceptance and priority review of Biologics License Application for Tabelecleucel for EBV+ PTLD treatment. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-24 13:02:20 UTC 2633 followers, XXX engagements
"$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X outcomes for ABTECT trials on Obefazimod an oral miR-124 enhancer for moderate to severe ulcerative colitis. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 02:02:42 UTC 2628 followers, XXX engagements
"$NBIX Neurocrine Biosciences reveals 1-year data demonstrating sustained effectiveness of CRENESSITY (crinecerfont) in adult patients at ENDO 2025. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-14 13:02:23 UTC 2633 followers, XXX engagements
"Nxera Pharma to get $15M from Neurocrine Biosciences after dosing first patient in Phase X trial for NBI-1117568. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-06-02 23:32:24 UTC 2633 followers, XXX engagements
"$ABVX PARIS:ABVX PARIS:FR Abivax reports encouraging Phase X results from ABTECT trials on Obefazimod for moderate to severe ulcerative colitis. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 21:02:48 UTC 2632 followers, 1498 engagements
"Novo Nordisk's Alhemo (concizumab) may be approved to treat haemophilia A and B without inhibitors following positive opinion from European regulatory authority. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-25 11:02:21 UTC 2633 followers, XXX engagements
"Windward Bio begins global Phase X asthma trial for WIN378 an anti-TSLP monoclonal antibody with potential as long-acting and best-in-disease treatment. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 13:02:26 UTC 2633 followers, XXX engagements
"Inotrem introduces revolutionary precision medicine approach for Nangibotide trials in septic shock treatment. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 13:32:31 UTC 2633 followers, XXX engagements
"$IONS CHMP suggests approving TRYNGOLZA (olezarsen) in the EU for familial chylomicronemia syndrome (FCS). More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-25 11:32:17 UTC 2633 followers, XXX engagements
"The Phase II trial of KX-826 Tincture XXX% for male adult AGA in China met its primary endpoint. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-25 13:18:36 UTC 2633 followers, XXX engagements
"$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X results in ABTECT trials for Obefazimod in moderate to severe ulcerative colitis. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 00:02:13 UTC 2629 followers, XXX engagements
"$VSTM Fast track designation granted to Verastem Oncology for VS-7375 in treating KRAS G12D-mutated Pancreatic Cancer. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-24 11:32:21 UTC 2632 followers, XXX engagements
"$PARIS:AB AB Science has received approval from several European countries to begin the confirmatory phase X study with masitinib in ALS. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-24 07:32:29 UTC 2631 followers, XXX engagements
"$VIR First patient dosed in Phase X trial of EGFR-targeting VIR-5525 for solid tumors by Vir Biotechnology. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-24 12:32:45 UTC 2633 followers, XXX engagements
"$IDYA IDEAYA Biosciences to present Phase X Clinical Trial of Neoadjuvant Darovasertib at ESMO 2025 for Primary Uveal Melanoma. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-24 13:32:29 UTC 2633 followers, XXX engagements
"First patient dosed in Phase 1b/2a trial of Procizumab a monoclonal antibody targeting shock's biological driver. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 10:02:22 UTC 2626 followers, XXX engagements
"$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X outcomes in ABTECT trials using Obefazimod for ulcerative colitis. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 23:02:21 UTC 2633 followers, XXX engagements
"$ARVN Arvinas reveals preclinical data for ARV-393 a PROTAC BCL6 Degrader at the 2025 EHA Congress. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-06-13 11:32:16 UTC 2633 followers, XXX engagements
"$HALO DARZALEX Faspro approved by EU Commission for adult patients with Smouldering Multiple Myeloma. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 16:02:22 UTC 2632 followers, XXX engagements
"$HOTH Hoth Therapeutics partners with VA for GDNF research targeting obesity and fatty liver. Study underway comparing GDNF to Semaglutide. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 12:32:16 UTC 2629 followers, XXX engagements
"$ONCY TSX:ONC Key Opinion Leader Event sheds light on Pelareorep's promising data in pancreatic and gastrointestinal fields highlighting its future potential. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 14:02:38 UTC 2633 followers, XXX engagements
"$PMN U.S. FDA grants ProMIS Neurosciences Fast Track Designation for PMN310 in Alzheimer's Disease treatment. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 12:32:18 UTC 2632 followers, XXX engagements
"$CADL Candel Therapeutics obtains EMA Orphan Designation for CAN-2409 for Pancreatic Cancer treatment. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-24 12:32:37 UTC 2632 followers, XXX engagements
"Reunion Neuroscience reports publication of RE104 Phase X Data in The Journal of Clinical Psychopharmacology. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 11:32:12 UTC 2626 followers, XXX engagements
"$BCDA BioCardia wants to meet with Japan PMDA to talk about getting approval for CardiAMP Cell Therapy in Ischemic Heart Failure. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-24 13:32:27 UTC 2633 followers, XXX engagements
"$RVMD Revolution Medicines announces publication in Science on Zoldonrasib a selective inhibitor for RAS(ON) G12D. Discovery and development detailed in peer-reviewed paper. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-24 20:02:22 UTC 2633 followers, XXX engagements
"$ALNY OXLUMO (lumasiran injection) is now reimbursed in Canada for treating Primary Hyperoxaluria Type X (PH1) in pediatric and adult patients. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-02 17:03:18 UTC 2627 followers, XXX engagements
"$PHGE BiomX starts Phase 2b trial for BX004 in Cystic Fibrosis patients first patient dosed successfully. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-14 13:02:26 UTC 2633 followers, XXX engagements
"$ZVRA MIPLYFFA (arimoclomol) by Zevra Therapeutics will be highlighted in presentations at the National Niemann Pick Disease Foundation Conference. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-11 11:32:12 UTC 2627 followers, XXX engagements
"$GILD European Medicines Agency grants Gilead positive CHMP opinions for twice-yearly Lenacapavir for HIV prevention under accelerated review. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-25 07:32:17 UTC 2632 followers, XXX engagements
"$RVMD FDA grants Breakthrough Therapy Designation to Revolution Medicines' Elironrasib. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 12:32:26 UTC 2633 followers, XXX engagements
"Diakonos Oncology reports first patient dosed in Phase X trial of DOC1021 for Glioblastoma. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 12:32:19 UTC 2627 followers, XXX engagements
"ReAlta Life Sciences releases data showing RLS-0071 decreases brain inflammation in preclinical hypoxic ischemic encephalopathy model. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 12:32:18 UTC 2626 followers, XXX engagements
"$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X outcomes for ABTECT trials on Obefazimod in treating Ulcerative Colitis. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 22:32:19 UTC 2630 followers, XXX engagements
"Canada approves Blenrep combos for relapsed/refractory multiple myeloma treatment. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 11:32:21 UTC 2632 followers, XXX engagements
"Bayer shares regulatory update on Elinzanetant for treating moderate to severe menopause-induced hot flashes. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-25 17:02:28 UTC 2633 followers, XXX engagements
"First patient dosed by OncoC4 with potential best-in-class PD-1/VEGF bispecific antibody AI-081 in Phase X of BIPAVE-001 trial for solid tumors in US. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 11:32:16 UTC 2626 followers, XXX engagements
"$CORT New Drug Application submitted by Corcept for Relacorilant intended for patients with Platinum-Resistant Ovarian Cancer. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-14 12:32:26 UTC 2633 followers, XXX engagements
"Apnimed announces positive results from Phase X trial of AD109 showing potential as first oral pill for obstructive sleep apnea. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 10:32:27 UTC 2632 followers, XXX engagements
"$ZVRA Zevra Therapeutics to present MIPLYFFA and OLPRUVA at SERGG Annual Meeting. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-18 12:02:15 UTC 2626 followers, XXX engagements
"Ammonium Chloride Market projected to reach $XXXX billion by 2034. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 15:33:16 UTC 2632 followers, XXX engagements
"$BMRN BioMarin shares five-year Phase X data confirming effectiveness and safety of ROCTAVIAN at International Society on Thrombosis and Haemostasis 2025 Congress. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-06-24 13:32:23 UTC 2633 followers, XXX engagements
"$SLDB FDA grants Fast Track Designation to Solid Biosciences for SGT-501 a first-of-its-kind gene therapy for CPVT. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 12:32:27 UTC 2632 followers, XXX engagements
"$IDYA IDEAYA and Hengrui reveal IDE849 for IASLC 2025. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 17:32:15 UTC 2630 followers, XXX engagements
"$CELC First patient in Phase X VIKTORIA-2 trial of Gedatolisib for HR+/HER2Advanced Breast Cancer dosed by Celcuity as first-line treatment. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-24 20:32:27 UTC 2633 followers, XXX engagements
"$KALV KalVista Pharmaceuticals gets favorable CHMP view for Sebetralstat for the management of Hereditary Angioedema Attacks. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-25 12:32:26 UTC 2633 followers, XXX engagements
"Polivy (polatuzumab vedotin) by Roche Canada is now publicly reimbursed in Quebec for first-line treatment of large B-cell lymphoma in adults. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 13:32:14 UTC 2627 followers, XXX engagements
"$ACET Adicet Bio dosed the first Systemic Sclerosis patient in Phase X trial of ADI-001 for Autoimmune Diseases. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-24 11:02:39 UTC 2633 followers, XXX engagements
"ANZUPGO Cream is the first FDA-approved treatment for moderate-to-severe Chronic Hand Eczema in adults. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 21:02:23 UTC 2633 followers, XXX engagements
"$REPL FDA issues Complete Response Letter to Replimune for RP1 Biologics License Application for Advanced Melanoma treatment. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 11:32:14 UTC 2626 followers, 1181 engagements
"$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X results for ABTECT 8-week induction trials of Obefazimod in treating moderate to severe ulcerative colitis. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 00:32:12 UTC 2629 followers, XXX engagements
"$ANNX Enrollment in pivotal Phase X ARCHER II trial of Vonaprument (formerly ANX007) for Dry AMD with Geographic Atrophy completed by Annexon. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-24 11:02:38 UTC 2633 followers, XXX engagements
"$IONS New study in JACI In Practice shows how donidalorsen benefits HAE patients who switched from other treatments in Phase X OASISplus data. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 11:32:23 UTC 2633 followers, XXX engagements
"$TNXP Tonix Pharmaceuticals will present new data on Mpox and smallpox vaccine TNX-801 at Vaccine Congress 2025. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-10 11:34:42 UTC 2633 followers, 3297 engagements
"$PRAX Praxis Precision Medicines granted FDA Breakthrough Therapy Designation for Relutrigine to treat seizures related to SCN2A and SCN8A Developmental and Epileptic Encephalopathies. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-17 12:32:31 UTC 2632 followers, XXX engagements
"$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X trials for ABTECT 8-week induction using Obefazimod for moderate to severe ulcerative colitis a first-of-its-kind oral miR-124 enhancer. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 21:32:29 UTC 2629 followers, XXX engagements
"$CGTX Cognition Therapeutics releases study examining how Zervimesine shields neurons and synapses in Alzheimer's disease. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 12:02:13 UTC 2630 followers, XXX engagements
"$IVBIY Innovent initiates Phase X trial for IBI354 a new HER2 ADC in platinum-resistant ovarian cancer. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-03-24 00:32:28 UTC 2627 followers, XXX engagements
"$BIIB SAGE CHMP gives positive opinion for ZURZUVAE in treating postpartum depression in women. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-25 11:32:16 UTC 2633 followers, XXX engagements
"$IRON Disc Medicine confirms plan to submit NDA for Bitopertin in EPP in October 2025 after positive pre-NDA meeting announcement. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 12:32:14 UTC 2633 followers, XXX engagements
"$IMAB I-Mab releases Givastomig Monotherapy Data in Clinical Cancer Research. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-06-30 20:32:41 UTC 2628 followers, XXX engagements
"$PARIS:SAN Sanofi's Sarclisa granted EU approval for treating eligible newly diagnosed multiple myeloma. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-25 05:04:47 UTC 2633 followers, XXX engagements
"$ATYR aTyr Pharma reports completion of Phase X EFZO-FIT study of Efzofitimod in patients with pulmonary sarcoidosis. Last patient visit announced. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 12:02:11 UTC 2630 followers, XXX engagements
"Eisai to share four-year efficacy and safety results for continuous treatment with lecanemab at Alzheimer's Association International Conference 2025. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 00:02:41 UTC 2632 followers, XXX engagements
"Prilenia and Ferrer give news on European process for Pridopidine in Huntington's Disease regulatory approval. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-25 13:32:29 UTC 2633 followers, XXX engagements
"$BMY Bristol Myers Squibb reports Phase X INDEPENDENCE Trial topline findings for Reblozyl in adults with Myelofibrosis-Associated Anemia. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-18 11:02:16 UTC 2633 followers, XXX engagements
"$GILD Gilead shares new research on lenacapavir's effectiveness for HIV prevention at IAS 2025. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-14 14:02:21 UTC 2631 followers, XXX engagements
"$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X outcomes for ABTECT 8-Week trial on Obefazimod for Ulcerative Colitis. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 22:02:19 UTC 2629 followers, XXX engagements
"Eisai will share four-year efficacy and safety data on continuous treatment with Lecanemab at the Alzheimer's Association International Conference 2025. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 08:02:08 UTC 2633 followers, XXX engagements
"$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X trial results for ABTECT 8-week induction studies on Obefazimod a unique oral miR-124 enhancer for ulcerative colitis. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 02:33:49 UTC 2633 followers, XXX engagements
"Long-acting fully human anti-TSLP antibody HBM9378/WIN378 enters global Phase X POLARIS trial for asthma treatment. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 14:02:40 UTC 2633 followers, XXX engagements
"$ADAG Adagene provides regulatory update on clinical plan for Muzastotug in microsatellite stable colorectal cancer after successful FDA meeting. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-15 11:02:20 UTC 2631 followers, XXX engagements
"$UNCY Unicycive Therapeutics releases Oxylanthanum Carbonate trial results in Clinical Journal of the American Society of Nephrology. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-24 12:32:42 UTC 2633 followers, XXX engagements
"$ALMS Alumis finishes enrolling patients in global LUMUS Phase 2b trial of ESK-001 an advanced oral TYK2 inhibitor for treating Systemic Lupus Erythematosus. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-24 11:32:20 UTC 2633 followers, XXX engagements
"$ZVRA Zevra Therapeutics reveals data from open label extension proving MIPLYFFA's long-term effectiveness in treating NPC published in Journal of Molecular Genetics and Metabolism. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-16 12:02:26 UTC 2627 followers, XXX engagements
"$LTRN Lantern Pharma announces full response in highly treated lymphoma patient with LP-284 in Phase X trial. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 12:02:16 UTC 2633 followers, XXX engagements
"$LLY CHMP has given a positive opinion on Donanemab for use in early symptomatic Alzheimer's disease. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-25 10:33:02 UTC 2633 followers, XXX engagements
"$ABVX PARIS:ABVX PARIS:FR Abivax reports promising Phase X findings on ABTECT 8-Week Induction Trials for Obefazimod an oral miR-124 enhancer for ulcerative colitis. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 20:34:09 UTC 2633 followers, 1011 engagements
"$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X results for ABTECT 8-Week Induction Trials of Obefazimod in patients with moderate to severe ulcerative colitis. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-22 23:32:13 UTC 2630 followers, XXX engagements
"$ENVB Enveric Biosciences gets second U.S. patent allowance for non-hallucinogenic mescaline derivatives in EVM401 Series. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 12:32:29 UTC 2633 followers, XXX engagements
"$KRYS Japan's Ministry of Health Labour and Welfare approves Krystal Biotech's VYJUVEK for treating Dystrophic Epidermolysis Bullosa. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-25 13:32:30 UTC 2633 followers, XXX engagements
"$ABVX PARIS:ABVX PARIS:FR Abivax reports successful Phase X outcomes in ABTECT 8-Week trials for Obefazimod a novel miR-124 enhancer for treatment of Ulcerative Colitis. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 01:02:12 UTC 2630 followers, XXX engagements
"$ENVB Enveric Biosciences' top drug candidate EB-003 shows promise in preclinical PTSD model with positive effects. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-15 13:32:18 UTC 2633 followers, 2776 engagements
"$RCKT FDA Clinical Hold on RP-A501 Trial causes Rocket Pharmaceuticals (RCKT) stock to plummet and leads to Class Action lawsuit by Hagens Berman. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 22:34:28 UTC 2633 followers, XXX engagements
"Kelun-Biotech's partner Windward Bio starts global Phase X trial for SKB378/WIN378 in asthma. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 13:32:32 UTC 2634 followers, XXX engagements
"$DYN Dyne Therapeutics receives FDA Breakthrough Therapy Designation for DYNE-101 in DM1 plans for accelerated approval discussed in Type C Meeting. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-06-17 11:02:32 UTC 2632 followers, XXX engagements
"$ORKA Oruka Therapeutics gets IND clearance for EVERLAST-A Phase 2a trial of ORKA-001 in Psoriasis. Phase X data to be detailed at EADV in September. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 11:32:29 UTC 2632 followers, XXX engagements
"Alkeus Pharmaceuticals to present Gildeuretinol data at ASRS 43rd Annual Meeting on July 29-August X. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 12:32:24 UTC 2633 followers, XXX engagements
"$JNJ Johnson & Johnson aims for US FDA approval of icotrokinra to change treatment for adults and teens with plaque psoriasis. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-21 13:02:14 UTC 2632 followers, XXX engagements
"Hillhurst Biopharmaceuticals administers first dose in Phase 2a trial for HBI-002 a new treatment for Sickle Cell Disease. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 20:02:34 UTC 2633 followers, XXX engagements
"$CMND CSE:CMND Clearmind Medicine finishes starting trial at top Israeli site for Phase I/IIa trial of CMND-100 for Alcohol Use Disorder. More Info: $XBI $IBB $XPH $PPH" @OzmosiHealth on X 2025-07-23 13:02:24 UTC 2633 followers, XXX engagements